True thyroid dysfunction can present with symptoms as wide-ranging as depression, mania, psychosis, or poor cognition.

Deep brain stimulation (DBS) has suddenly begun popping up in both the medical journals and the mainstream media as a potential treatment for treatment resistant depression.

The combination of buprenorphine and naloxone (Suboxone) has become a popular replacement therapy for heroin dependence. However, it’s not yet clear how effective it is for prescription opioid dependence, or whether adjunctive counseling provides any additional benefit over the drug alone.

“Self-management” is a newly popular buzzword among clinicians treating the seriously mentally ill.

For years, we have read articles about the promise of pharmacogenetic testing to help us choose and monitor medication treatment.

We know that the postpartum period is a risky time for women who have a history of depression, especially if they experienced postpartum depression in the past. But several questions about mood and pregnancy are still unanswered.

It has been over a year now since the approval of vilazodone (Viibryd). As you may recall from our review of the drug in TCPR April 2011, vilazodone is an SSRI with partial agonism at the 5HT1A receptor.

Whether you see your patients quarterly, monthly, or even weekly, you certainly are not with them as much as their cell phones are.

Omega-3 fatty acids have been extolled as a treatment for everything from depression to high blood pressure. But how do they stack up for ADHD?

Clinical trials of both antidepressants and the antipsychotic olanzapine (Zyprexa) have yielded disappointing results, with no clear benefit of medications over placebo for the core symptoms of anorexia.